Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016297 | 0.91 | HTT (0.39) | TSHRNUDT1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL22576451 | 0.91 | HTT (0.39) | TSHRNUDT1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL16885185 | 0.82 | NUDT1 (0.37) | NUDT1SMN1; SMN2ALDH1A1KDM4EHTT | |
| SCHEMBL12391026 | 0.81 | CYP2D6 (0.42) | TSHRNUDT1SMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL31201045 | 0.80 | NUDT1 (0.40) | NUDT1ALDH1A1GRM4POLB | |
| SCHEMBL6918344 | 0.79 | CYP3A4 (0.39) | TSHRNUDT1SMN1; SMN2HSD17B10 | |
| SCHEMBL937563 | 0.79 | NUDT1 (0.35) | NUDT1 | |
| SCHEMBL31201109 | 0.79 | NUDT1 (0.59) | TSHRNUDT1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL2014330 | 0.78 | RECQL (0.38) | NUDT1ALDH1A1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL3059054 | 0.78 | MAPT (0.36) | NUDT1SMN1; SMN2KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4651944-A1 | INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4554938-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4543544-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119894879-A | Tyrosine kinase 2 inhibitors and uses thereof | 渤健马萨诸塞州股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119866338-A | Tyrosine kinase 2 inhibitors and uses thereof | 渤健马萨诸塞州股份有限公司 | 2025-04-22 | — | — | CN | disclosed |
| WO-2024233767-A1 | INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024015497-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023250064-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | ALTMAN MICHAEL D (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| WO-2011075515-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
| CN-100415724-C | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2008-09-03 | — | — | CN | disclosed |
| US-6846827-B1 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-01-25 | — | — | US | disclosed |
| EP-1226126-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| CN-1378537-A | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2002-11-06 | — | — | CN | disclosed |
| EP-1226126-A1 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001027089-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | TSHR 1264/4885NUDT1 1970/4885SMN1; SMN2 3605/4885 |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | TSHR 2833/4885NUDT1 577/4885SMN1; SMN2 4226/4885 |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | SYK, BTK, LCK | TSHR 2833/4885NUDT1 577/4885SMN1; SMN2 4226/4885 |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | TYK2, ERBB2, ROS1 | TSHR 469/4885NUDT1 2715/4885SMN1; SMN2 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.